CAPITOL HILL STRATEGIES, LLC for AMGEN
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M BRAIN | Asst. to the President, Dp. Chief of Staff W&M Cmte. |
| A. J. WOJCIAK | Senior Legislative Asst., Cong. Earl Pomeroy |
Medicare/Medicaid MMM
H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019, provisions relating to prescription drug pricing and intellectual property rights.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHARLES M BRAIN | Asst. to the President, Dp.Chief Staff W&M Cmte |
| A. J. WOJCIAK | Senior Legislative Asst., Cong. Earl Pomeroy |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.